Figure 5
The effect of inhibitors SB202190, PD98059, LY294002 and AG490 on BMSCs-OVX treated with akermanite extract.
(A) Western blot assay for the expression of p-P38, p-ERK, p-AKT and p-STAT3 for BMSCs-OVX cultured in akermanite extract with inhibitors SB202190, PD98059, LY294002 and AG490 for 90 min, respectively; (B) The quantitative assay for the ratios of p-P38/P38 (a), p-ERK/ERK (b), p-AKT/AKT (c) and p-STAT3/STAT3 (d) for BMSCs-OVX cultured in akermanite extract with inhibitors SB202190, PD98059, LY294002 and AG490 for 90 min, respectively; (C) ALP staining for BMSCs-OVX cultured in akermanite extract with inhibitors SB202190, PD98059, LY294002 and AG490 for 10 days, respectively; (D) Rea-time PCR analysis of Runx2 (a), BMP-2 (b), BSP (c), OPN (d), OCN (e), OPG (f), RANKL (g), TNF-α (h), VEGF (i) and ANG-1 (j) for BMSCs-OVX cultured in akermanite extract with inhibitors SB202190, PD98059, LY294002 and AG490 for 7 days, respectively. BMSCs-OVX cultured in akermanite extract without any inhibitors was treated as akermanite group. ★indicates significant differences as compared with akermanite group, p < 0.05. Scale bar = 10 mm.
